SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has initiated a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44, a multi-receptor peptide designed to treat obesity and type 2 diabetes. The program is aligned with U.S. Food and Drug Administration (FDA) requirements and is intended to support an Investigational New Drug (IND) application, marking a critical step before first-in-human clinical trials.
The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species. Preclinical results for GEP-44 position it head-to-head with market leaders such as Ozempic, Mounjaro, and Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
This development comes as the global GLP-1 receptor agonist market is projected to reach between $100 billion and $200 billion by 2030, according to J.P. Morgan estimates, with approximately 25 million patients in the United States alone expected to use GLP-1 therapies by that time. SureNano is positioning itself as an agile entrant in this rapidly expanding market, having secured licensing rights to the GEP-44 compound developed by Syracuse University.
The company is also exploring the acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments, signaling a broader pharmaceutical focus. SureNano’s transition toward a pharmaceutical model follows its acquisition of GlucaPharm, now operating in the GLP market.
For more information on SureNano Science, visit the company’s newsroom at https://ibn.fm/SURNF.
Forward-looking information in this release involves risks and uncertainties, and actual results may differ materially. Factors include market prices, study and trial results, continued availability of capital and financing, and general economic conditions. Readers should not place undue reliance on forward-looking statements.
